Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia:

Inclusion Criteria: 1. Participant must be between 50 and 80 years old. 2. Participant has signed and dated the appropriate Informed Consent document. 3. International Prostate Symptom Score (IPSS) ≥8 and ≤30 4. Prostate volume ≥30gram and ≤80gram 5. Peak urinary flow rate (Qmax) ≥5 ml/sec and ≤15ml/sec 6. Post void residual volume ≤150ml Exclusion Criteria: 1. Current or recurrent urinary tract infection (UTI), prostatitis, gross hematuria (blood in urine without a known cause), or a history of urinary retention. 2. Participant has a history of prostate, bladder or urethral cancer. 3. Participant has undergone pelvic radiation or systemic chemotherapy. 4. Participant has undergone intravesical chemotherapy. 5. Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition (except from BPH) associated with LUTS, any neurological disease or disorder affecting the bladder. 6. Participant has undergone prostate surgery 7. Participant with penile or urinary sphincter implants. 8. Diagnosed neurological conditions known to affect bladder function (e.g., multiple sclerosis, Parkinson's disease, or neurogenic bladder). 9. Significant medical conditions (e.g., unstable cardiac arrhythmias, uncontrolled diabetes, severe renal impairment) that pose an unreasonable risk to the patient or might interfere with study results. 10. Participant has been diagnosed with cancer during the last 5 years or had any surgery in the pelvis. 11. Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.